Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (21-30 of 284) with videos related to

Pageof 29
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2006
Paraneoplastic syndromes associated with small cell lung cancerLeena Gandhi, Bruce E Johnson
American Journal of Respiratory and Critical Care Medicine|July 12, 2013
The impact of genomic changes on treatment of lung cancerStephanie Cardarella, Bruce E Johnson
Obstetrics and Gynecology|May 2, 2008
Preoperative evaluation of the gynecologic patient: considerations for improved outcomesBruce E Johnson, Joann Porter
The Journal of Thoracic and Cardiovascular Surgery|April 17, 2012
Adjuvant chemotherapy for surgically resected non-small cell lung cancerStephanie Heon, Bruce E Johnson
Annals of Internal Medicine|January 17, 2018
Pooled RCTs: In postmenopausal women, hormone therapy for 6 to 7 years did not affect mortality at 18 yearsBruce E Johnson, Cynda Ann Johnson
Hematology/Oncology Clinics of North America|April 20, 2004
Basic treatment considerations using chemotherapy for patients with small cell lung cancerBruce E Johnson, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancerBruce E Johnson, Michael S Rabin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitorsPasi A Jänne, Bruce E Johnson
Annals of Internal Medicine|June 17, 2009
ACP Journal Club. Postmenopausal hormone therapy was cost-effective when started at age 50 years but not at 65 yearsBruce E Johnson, Cynda Ann Johnson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?Bruce E Johnson, Pasi A Jänne
Pageof 29

Showing results (21-30 of 284) with videos related to

Sort By:
Pageof 29
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2006
Paraneoplastic syndromes associated with small cell lung cancerLeena Gandhi, Bruce E Johnson
American Journal of Respiratory and Critical Care Medicine|July 12, 2013
The impact of genomic changes on treatment of lung cancerStephanie Cardarella, Bruce E Johnson
Obstetrics and Gynecology|May 2, 2008
Preoperative evaluation of the gynecologic patient: considerations for improved outcomesBruce E Johnson, Joann Porter
The Journal of Thoracic and Cardiovascular Surgery|April 17, 2012
Adjuvant chemotherapy for surgically resected non-small cell lung cancerStephanie Heon, Bruce E Johnson
Annals of Internal Medicine|January 17, 2018
Pooled RCTs: In postmenopausal women, hormone therapy for 6 to 7 years did not affect mortality at 18 yearsBruce E Johnson, Cynda Ann Johnson
Hematology/Oncology Clinics of North America|April 20, 2004
Basic treatment considerations using chemotherapy for patients with small cell lung cancerBruce E Johnson, Pasi A Jänne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancerBruce E Johnson, Michael S Rabin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitorsPasi A Jänne, Bruce E Johnson
Annals of Internal Medicine|June 17, 2009
ACP Journal Club. Postmenopausal hormone therapy was cost-effective when started at age 50 years but not at 65 yearsBruce E Johnson, Cynda Ann Johnson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?Bruce E Johnson, Pasi A Jänne
Pageof 29